These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 21727088

  • 21. 2'-fluoro-modified pyrimidines enhance affinity of RNA oligonucleotides to HIV-1 reverse transcriptase.
    Gruenke PR, Alam KK, Singh K, Burke DH.
    RNA; 2020 Nov; 26(11):1667-1679. PubMed ID: 32732393
    [Abstract] [Full Text] [Related]

  • 22. Screening of novel inhibitors of HIV-1 reverse transcriptase with a reporter ribozyme assay.
    Yamazaki S, Famulok M.
    Methods Mol Biol; 2009 Nov; 535():187-99. PubMed ID: 19377995
    [Abstract] [Full Text] [Related]

  • 23. HIV-1 reverse transcriptase mutations that confer decreased in vitro susceptibility to anti-RT DNA aptamer RT1t49 confer cross resistance to other anti-RT aptamers but not to standard RT inhibitors.
    Fisher TS, Joshi P, Prasad VR.
    AIDS Res Ther; 2005 Oct 05; 2():8. PubMed ID: 16207371
    [Abstract] [Full Text] [Related]

  • 24. Identification of specific HIV-1 reverse transcriptase contacts to the viral RNA:tRNA complex by mass spectrometry and a primary amine selective reagent.
    Kvaratskhelia M, Miller JT, Budihas SR, Pannell LK, Le Grice SF.
    Proc Natl Acad Sci U S A; 2002 Dec 10; 99(25):15988-93. PubMed ID: 12461175
    [Abstract] [Full Text] [Related]

  • 25. Aptamer displacement identifies alternative small-molecule target sites that escape viral resistance.
    Yamazaki S, Tan L, Mayer G, Hartig JS, Song JN, Reuter S, Restle T, Laufer SD, Grohmann D, Kräusslich HG, Bajorath J, Famulok M.
    Chem Biol; 2007 Jul 10; 14(7):804-12. PubMed ID: 17656317
    [Abstract] [Full Text] [Related]

  • 26. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
    Fattorusso C, Gemma S, Butini S, Huleatt P, Catalanotti B, Persico M, De Angelis M, Fiorini I, Nacci V, Ramunno A, Rodriquez M, Greco G, Novellino E, Bergamini A, Marini S, Coletta M, Maga G, Spadari S, Campiani G.
    J Med Chem; 2005 Nov 17; 48(23):7153-65. PubMed ID: 16279773
    [Abstract] [Full Text] [Related]

  • 27. The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor.
    Jaeger J, Restle T, Steitz TA.
    EMBO J; 1998 Aug 03; 17(15):4535-42. PubMed ID: 9687519
    [Abstract] [Full Text] [Related]

  • 28. Poly-Target Selection Identifies Broad-Spectrum RNA Aptamers.
    Alam KK, Chang JL, Lange MJ, Nguyen PDM, Sawyer AW, Burke DH.
    Mol Ther Nucleic Acids; 2018 Dec 07; 13():605-619. PubMed ID: 30472639
    [Abstract] [Full Text] [Related]

  • 29. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.
    Das K, Bauman JD, Clark AD, Frenkel YV, Lewi PJ, Shatkin AJ, Hughes SH, Arnold E.
    Proc Natl Acad Sci U S A; 2008 Feb 05; 105(5):1466-71. PubMed ID: 18230722
    [Abstract] [Full Text] [Related]

  • 30. Cutting into the Substrate Dominance: Pharmacophore and Structure-Based Approaches toward Inhibiting Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H.
    Wang L, Sarafianos SG, Wang Z.
    Acc Chem Res; 2020 Jan 21; 53(1):218-230. PubMed ID: 31880912
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
    Das K, Ding J, Hsiou Y, Clark AD, Moereels H, Koymans L, Andries K, Pauwels R, Janssen PA, Boyer PL, Clark P, Smith RH, Kroeger Smith MB, Michejda CJ, Hughes SH, Arnold E.
    J Mol Biol; 1996 Dec 20; 264(5):1085-100. PubMed ID: 9000632
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance.
    Xavier Ruiz F, Arnold E.
    Curr Opin Struct Biol; 2020 Apr 20; 61():113-123. PubMed ID: 31935541
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Study of binding stoichiometries of the human immunodeficiency virus type 1 reverse transcriptase by capillary electrophoresis and laser-induced fluorescence polarization using aptamers as probes.
    Fu H, Guthrie JW, Le XC.
    Electrophoresis; 2006 Feb 20; 27(2):433-41. PubMed ID: 16331583
    [Abstract] [Full Text] [Related]

  • 37. Highly efficient inhibition of human immunodeficiency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles.
    Shiang YC, Ou CM, Chen SJ, Ou TY, Lin HJ, Huang CC, Chang HT.
    Nanoscale; 2013 Apr 07; 5(7):2756-64. PubMed ID: 23429884
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Quantum computational analysis for drug resistance of HIV-1 reverse transcriptase to nevirapine through point mutations.
    He X, Mei Y, Xiang Y, Zhang DW, Zhang JZ.
    Proteins; 2005 Nov 01; 61(2):423-32. PubMed ID: 16114038
    [Abstract] [Full Text] [Related]

  • 40. Crystal structures of an N-terminal fragment from Moloney murine leukemia virus reverse transcriptase complexed with nucleic acid: functional implications for template-primer binding to the fingers domain.
    Najmudin S, Coté ML, Sun D, Yohannan S, Montano SP, Gu J, Georgiadis MM.
    J Mol Biol; 2000 Feb 18; 296(2):613-32. PubMed ID: 10669612
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.